Valeant Pharma (VRX) Trades at New Lows Amid Ex-Executive Probe

October 31, 2016 3:59 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Valeant Pharma (NYSE: VRX) is trading at fresh 52-week lows following reports ex-CEO, Michael Pearson and ex.-CFO, Howard Schiller, are the focus of criminal probe related potential accounting fraud tied to the company's hidden Philidor Rx Services company.

Shares last traded down 12.4% to $17.83.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Short Sales, Trader Talk

Add Your Comment